AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises

AbbVie Q3 2026 Results show worldwide net revenues of $17.404 billion for the quarter ended September 30, 2026, an increase of 10.3 percent on a reported basis and 10.5 percent on an operational basis. AbbVie (NYSE: ABBV) published the figures on October 30, 2026, from North Chicago, Illinois. Diluted earnings per share (EPS) reached $2.37 on a GAAP basis, while adjusted diluted EPS was $3.82. Both measures rose by more than 100 percent, and both absorbed an unfavorable $0.11 per share impact from acquired IPR&D and milestones expense.

Chairman and chief executive officer Robert A. Michael pointed to “solid execution across our diverse portfolio” and to the completed acquisition of Apogee Therapeutics. He said the company is again increasing full-year guidance and raising its quarterly dividend.

Within AbbVie Q3 2026 Results, immunology again carried the quarter. Global immunology net revenues were $9.165 billion, up 16.3 percent on a reported basis, with Skyrizi at $5.776 billion, Rinvoq at $2.706 billion and Humira at $683 million. The quarter also brought two FDA approvals, new late-stage data in oncology and neuroscience, and a raised 2026 adjusted EPS range, all covered below.

AbbVie Q3 2026 Results Show 10.3% Revenue Growth and GAAP EPS of $2.37

In AbbVie Q3 2026 Results, the GAAP gross margin ratio in the third quarter was 75.4 percent, and the adjusted gross margin ratio was 85.1 percent. Selling, general and administrative (SG&A) expense was 23.5 percent of net revenues on a GAAP basis and 21.2 percent adjusted. Research and development (R&D) expense was 14.7 percent of net revenues on a GAAP basis and 13.9 percent adjusted. Acquired IPR&D and milestones expense was 1.2 percent of net revenues.

Learn More

Abbott Q3 2026 Results: Abbott (NYSE: ABT) Posts 14.5% Sales Growth, Reaffirms Full-Year EPS Guidance Midpoint

The operating margin ratio was 36.0 percent on a GAAP basis and 48.7 percent adjusted. Operating earnings were $6.267 billion, compared with $1.904 billion in the third quarter of 2025. Net earnings attributable to AbbVie Inc. were $4.218 billion, compared with $186 million a year earlier. The prior-year quarter included $2.68 billion of acquired IPR&D and milestones expense, which carried a $1.50 per share unfavorable impact, and an $847 million intangible asset impairment tied to the Resonic and Durysta assets.

Below the operating line, net interest expense was $700 million on a GAAP basis and $688 million adjusted. The tax rate was 12.6 percent on a GAAP basis and 13.6 percent adjusted. For the first nine months of 2026, net revenues were $49.396 billion, up 10.9 percent on a reported basis, with diluted EPS of $4.79 and adjusted diluted EPS of $10.12. The table below summarizes the headline metrics.

AbbVie Q3 2026 Results by Portfolio: Immunology, Neuroscience, Oncology and Aesthetics

Immunology net revenues were $9.165 billion, up 16.3 percent reported and 16.6 percent operational. Global Skyrizi (risankizumab) net revenues rose 22.7 percent to $5.776 billion, split between $5.019 billion in the United States and $757 million internationally. Global Rinvoq (upadacitinib) net revenues rose 23.9 percent to $2.706 billion. Humira net revenues fell 31.2 percent to $683 million.

Neuroscience was a standout in AbbVie Q3 2026 Results, with net revenues of $3.389 billion, up 19.4 percent reported. Vraylar generated $1.068 billion, up 14.3 percent, and Botox Therapeutic generated $1.080 billion, up 9.8 percent. Ubrelvy reached $449 million, up 26.9 percent, and Qulipta reached $398 million, up 38.2 percent on a reported basis, for a combined $847 million. Vyalev contributed $286 million in the quarter.

Learn More

AbbVie Valkai AI Partnership Deploys Purpose-Built AI Across Targeted Clinical Development Areas

Oncology net revenues in AbbVie Q3 2026 Results were $1.696 billion, up 0.8 percent reported. Venclexta delivered $803 million, up 10.7 percent, while Imbruvica fell 26.1 percent to $522 million. Elahere reached $224 million, up 31.0 percent, and Epkinly reported $108 million, up 57.7 percent. U.S. oncology revenue declined 5.7 percent while international oncology revenue rose 11.1 percent.

Aesthetics net revenues were $1.176 billion, down 1.4 percent reported. Botox Cosmetic generated $669 million, up 4.9 percent, and the Juvederm Collection generated $222 million, down 11.9 percent. Among other key products, Creon reported $361 million, Linzess $339 million and Mavyret $265 million. The data below is reproduced from the company’s key product revenue schedule.

AbbVie Q3 2026 Results and Pipeline Milestones: Apogee, Juvmo, Skyrizi and Etentamig

AbbVie completed its acquisition of Apogee Therapeutics, adding zumilokibart, a late-stage half-life extended IL-13 antibody for atopic dermatitis, and APG273, a long-acting IL-13 and TSLP combination for asthma. At the 2026 European Academy of Dermatology and Venereology (EADV) Congress, Phase 2 APEX Part B data showed all three zumilokibart dose regimens met the primary EASI-75 endpoint at week 16 versus placebo. Acquisition and integration costs in the quarter primarily reflect the Apogee transaction.

Among the pipeline updates tied to AbbVie Q3 2026 Results, the U.S. Food and Drug Administration approved Skyrizi for subcutaneous induction in moderately to severely active Crohn’s disease, supported by the Phase 3 AFFIRM study. The agency also approved a prescribing information update allowing clinicians to use judgment on tuberculosis testing across all Skyrizi indications, and AbbVie submitted a matching application to the European Medicines Agency. Phase 2a TARGET-CD data for ABBV-466, a Skyrizi plus ABBV-382 combination, showed higher endoscopic remission at Week 12 than either monotherapy, and Rinvoq vitiligo studies Viti-Up-1 and Viti-Up-2 showed continued repigmentation through week 76.

In neuroscience, the FDA approved Juvmo (tavapadon) tablets for adults with Parkinson’s disease, described as the only selective D1/D5 receptor agonist for the indication and supported by the Phase 3 TEMPO program. The Phase 3 LUNA study of Qulipta (atogepant) in menstrual migraine met its primary endpoint and all eight ranked secondary endpoints. Separately, Phase 3 INTREPID results showed lutikizumab met its primary HiSCR 75 endpoint at Week 16 in hidradenitis suppurativa, with regulatory submissions planned for the second half of 2027, which is a forward-looking statement.

On the oncology side of AbbVie Q3 2026 Results, AbbVie submitted a Biologics License Application for etentamig in relapsed or refractory multiple myeloma, citing Phase 3 CERVINO results with a 74 percent overall response rate. AbbVie and Genmab reported positive Phase 3 EPCORE DLBCL-2 topline results for Epkinly with R-CHOP, with a 51 percent reduction in the risk of progression or death. The FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A), and Allergan Aesthetics announced FDA acceptance of a supplemental BLA for Botox Cosmetic in masseter muscle prominence. AbbVie also reported Phase 1 data for ABBV-295, an obesity amylin analog with an approximately 11- to 12-day half-life, and announced AI collaborations with Valkai and Iambic.

AbbVie Q3 2026 Results Outlook: Raised EPS Guidance and 5.2% Dividend Increase

AbbVie raised its 2026 adjusted diluted EPS guidance from a range of $13.76 to $13.96 to a range of $13.95 to $13.99. The new range includes an unfavorable $0.69 per share impact from acquired IPR&D and milestones expense incurred year-to-date through the third quarter. The guidance excludes any acquired IPR&D and milestones that may be incurred beyond the third quarter, because the company says they cannot be reliably forecasted.